IPO Details
Bidding Dates
19 Feb 24 - 22 Feb 24
Price Range ₹
75 - 79
Total Equity
₹ 40.68Cr
Lot Size
1600
Exchange Status
NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
0.00×
Qualified Institutional Buyers
0.00×
Employees
0.00×
Retail Investors
0.00×
Total subscription Rate
0.00×
IPO Timeline
Offer start
19 Feb 2024
Offer end
22 Feb 2024
Allotment
23 Feb 2024
Refund initiation
26 Feb 2024
Demat transfer
26 Feb 2024
Listing
27 Feb 2024
Offer start
19 Feb 2024
Offer end
22 Feb 2024
Allotment
23 Feb 2024
Refund initiation
26 Feb 2024
Demat transfer
26 Feb 2024
Listing
27 Feb 2024
About Company
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in the manufacturing and trading of high-quality, affordable medicines, particularly generic drugs. Adhering to WHO-GMP guidelines, the company has obtained ISO 9001:2015 certification from a reputable EuroUK certification body, underscoring its commitment to quality standards. Zenith Drugs Limited offers a diverse product portfolio that includes ORS Powder, Liquid Orals, Ointments, Liquid Externals, and Capsules. With approval from the Food & Drugs Administration for over 600 products, the company currently produces 325 of them. Additionally, Zenith Drugs Limited is expanding its operations with the establishment of a new manufacturing facility in Village Muradpura, Depalpur, Indore, Madhya Pradesh.
Year Founded
15-11-2000
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 100 | 69.98 |
| Share Capital | 12000000 | 12000000 |
Offer to Public
51,48,800.00 Cr
Project Details
- Working Capital Requirements - 453.273cr
- Existing Manufacturing Block Upgradation - 21.059cr
- Purchase of Machinery & Equipments for Setting up New Unit - 106.099cr
- General Corporate Purposes - 88.397cr
Objectives
- a) Purchase of Machinery & Equipments for Setting up New Unitb) Existing Manufacturing Block Upgradationc) Working Capital Requirementsd) General Corporate Purposes.
Highlights
- Zenith Drugs Limited specializes in manufacturing and trading high-quality, affordable generic medicines, catering to a wide range of medical needs and ensuring accessibility to essential healthcare products.
- Adherence to WHO-GMP guidelines and ISO 9001:2015 certification reflects the company's commitment to maintaining high-quality standards in its manufacturing processes, ensuring the safety and efficacy of its products.
- Zenith Drugs Limited exports its products to multiple countries across Central America, the Caribbean, Africa, and Southeast Asia, expanding its market reach and potential for revenue growth.
- The company's product portfolio includes various pharmaceutical forms such as ORS powder, liquid orals, ointments, liquid externals, and capsules, allowing it to cater to different patient preferences and medical requirements.
- Specialization in third-party manufacturing enables Zenith Drugs Limited to collaborate with renowned pharmaceutical companies for white label manufacturing, leveraging its expertise and infrastructure to meet the manufacturing needs of its clients.
Challenges
- Operating in multiple countries may pose challenges related to regulatory compliance and approval processes, as each country may have different regulatory requirements for pharmaceutical products.
- Reliance on export markets for revenue generation exposes Zenith Drugs Limited to risks associated with fluctuations in foreign exchange rates, changes in import regulations, and geopolitical uncertainties.
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Zenith Drugs Limited may face challenges in differentiating its products and maintaining competitiveness in the market.
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Zenith Drugs Limited may face challenges in differentiating its products and maintaining competitiveness in the market.
- Managing a workforce comprising both permanent and contract employees may pose challenges related to labor management, including recruitment, training, retention, and compliance with labor laws and regulations.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2024 | 13,497.19 | 1,714.88 | 488.04 | 488.08 | 4.0673 |
| 2022 | 6,858.47 | 40.00 | 312.86 | 313.82 | 2.6152 |
| 2023 | 9,792.48 | 40.00 | 312.86 | 313.82 | 2.6152 |
